| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Apr 28, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on June 14,...
-
Apr 21, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision...
-
Apr 19, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...
-
Apr 13, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...
-
Apr 12, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...
-
Mar 14, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Barclays Capital 2011 Global...
-
Mar 1, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the...
-
Feb 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi 2011 Global Health Care...
-
Feb 22, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone...